Dr. James Wheless, MD

Medicare patients and services

Medicare patients, 2024

15

Services billed

31

Patients’ average age

33

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 16 companies reported 210 payments worth $148,710 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Tennessee →

Industry-funded research

Named as a principal investigator on 11 industry-funded studies in 2025, from 7 companies. The companies reported $309,274 in research payments for these studies, mostly to the institutions running them.

• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
  UCB Biosciences Inc. · Completed · NCT06118255
• Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
  Sk Life Science, Inc. · Completed · NCT05067634
• A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
  H. Lundbeck A S
• Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
  Immedica Pharma US, Inc. · Terminated · NCT05604170
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
  H. Lundbeck A S
• A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
  H. Lundbeck A S
• A Study to evaluate the pharmacokinetics, safety, and tolerability of zonisamide oral suspension (100mg/5ml) to determine a dosing regimen in children 1 month to 17 years of age with partial-onset seizures
  Azurity Pharmaceuticals, Inc.
• Tuberous Sclerosis Syndrome and Epidiolex: NonSeizure Outcomes Mixed Methods Research
  Jazz Pharmaceuticals Inc.
• Evaluating the safety of fenfluramine (Fintepla) for Dravet syndrome, Lennox-Gastaut syndrome, and other epilepsy patients aged less than 2 years at treatment initiation: a US retrospective chart review.
  UCB Biosciences Inc.
• An open-label, single-dose, pharmacokinetics study of valtoco with open-label safety period in pediatric subjects with epilepsy
  Neurelis, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Child Neurology clinicians in Memphis

• Richard S. Finkel, MD
• Stephen P. Fulton, M.D.
• Connor W. Gatewood, MD
• Ankita Ghosh, MD
• Emily Hanzlik, MD
• Masanori Igarashi, MD
• Robin L. Jack, MD
• Kathleen Nicole M. Jalandoni, MD